RaySearch Laboratories AB (publ) today announces the release of RayStation®* v2026, the latest version of its treatment planning system. The new release introduces enhanced support for reirradiation, integrated patient-specific quality assurance, expanded automation, and further improvements in particle therapy.
As cancer treatments improve and the population ages, a larger portion of patients may receive radiotherapy more than once during their lifetime. When radiotherapy is delivered after a previous course of radiotherapy, this is known as reirradiation. RayStation’s reirradiation support helps users account for previously delivered dose, anatomical changes, and radiobiological effects when combining treatments separated in time.
The new release also introduces a new module for more streamlined patient-specific quality assurance for treatment machines using on-board imaging devices. This provides means to avoid time-consuming manual setups of measurement devices. Automation remains a key focus area, and RayStation v2026 introduces expanded capabilities for automated and advanced treatment planning. Examples include enhanced automation of proton planning workflows through the introduction of plan generation protocols, further improvements in automated planning, updates to Plan Explorer, and more than 30 new deep learning segmentation models, including models for pediatric cases. The deep learning planning functionality for v2026 includes new and updated models for breast locoregional treatments, lung proton cases, and prostate with seminal vesicles and lymph nodes.
On the particle therapy side, new features further strengthen RayStation’s particle therapy capabilities: support for proton static arc planning for patients treated in upright positions, enhanced support for Hitachi proton and carbon ion systems, and proton optimization using the GPU, enabling substantially shorter optimization times, especially for the most complex patient cases.
“RayStation v2026 is an important step in the continued development of our treatment planning platform,” says Johan Löf, founder and CEO of RaySearch Laboratories. ”With new support for reirradiation, stronger particle therapy capabilities and further expansion of deep learning segmentation and planning, we are helping clinics manage increasingly advanced treatments with greater efficiency and confidence.”
To learn more about RayStation v2026 and explore the full set of new features, please visit the RayStation v2026 release page: https://www.raysearchlabs.com/raystation-v2026/
For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB
Tel: +46 (0) 8 510 530 00
Carolina Strömlid, Head of Investor Relations, RaySearch Laboratories AB
Tel: +46 (0) 708 807 173
ir@raysearchlabs.com
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure, and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems. RaySearch’s software has been sold to over 1,200 clinics in 51 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003 (STO: RAY B). More information is available at raysearchlabs.com.
About RayStation
RayStation®* is a flexible, innovative treatment planning system chosen by many leading cancer centers worldwide. It combines advanced treatment planning capabilities for external beam therapy with photons, electrons and protons, as well as helium and carbon ions, and supports a wide range of treatment machines. RayStation is designed to provide one control center for all treatment planning needs and also integrates with RayCare®*.
* Subject to regulatory clearance in some markets. Some functionality described in the RayStation v2026 materials is identified as investigational or subject to regulatory clearance in some markets.